¼¼°èÀÇ ½ÉÀåÇÐ ºÐ¾ß ÀΰøÁö´É(AI) ½ÃÀå ±Ô¸ð, Á¡À¯À², ¾÷°è ºÐ¼® º¸°í¼­ : ÄÄÆ÷³ÍÆ®º°, ¿ëµµº°, º´»óº°, Áö¿ªº°, Àü¸Á°ú ¿¹Ãø(2025-2032³â)
Global Artificial Intelligence In Cardiology Market Size, Share & Industry Analysis Report By Component, By Application, . By Medical Condition, By Regional Outlook and Forecast, 2025 - 2032
»óǰÄÚµå : 1768270
¸®¼­Ä¡»ç : KBV Research
¹ßÇàÀÏ : 2025³â 06¿ù
ÆäÀÌÁö Á¤º¸ : ¿µ¹® 311 Pages
 ¶óÀ̼±½º & °¡°Ý (ºÎ°¡¼¼ º°µµ)
US $ 3,600 £Ü 5,028,000
PDF (Single User License) help
PDF º¸°í¼­¸¦ 1¸í¸¸ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. ÅØ½ºÆ®ÀÇ Copy & Paste °¡´ÉÇÕ´Ï´Ù. Àμ⠰¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.
US $ 4,320 £Ü 6,034,000
PDF (Multi User License) help
PDF º¸°í¼­¸¦ µ¿ÀÏ ±â¾÷ÀÇ 10¸í±îÁö ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. ÅØ½ºÆ®ÀÇ Copy & Paste °¡´ÉÇÕ´Ï´Ù. Àμ⠰¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.
US $ 6,048 £Ü 8,448,000
PDF (Corporate User License) help
PDF º¸°í¼­¸¦ µ¿ÀÏ ±â¾÷ÀÇ ¸ðµç ºÐÀÌ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. ÅØ½ºÆ®ÀÇ Copy & Paste °¡´ÉÇÕ´Ï´Ù. Àμ⠰¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.


Çѱ۸ñÂ÷

¼¼°èÀÇ ½ÉÀåÇÐ ºÐ¾ß ÀΰøÁö´É(AI) ½ÃÀå ±Ô¸ð´Â ¿¹Ãø ±â°£ Áß¿¡ 32.3%ÀÇ ¿¬Æò±Õ º¹ÇÕ ¼ºÀå·ü(CAGR)·Î ¼ºÀåÇÏ¿© 2032³â±îÁö 182¾ï 1,000¸¸ ´Þ·¯¿¡ À̸¦ °ÍÀ¸·Î ¿¹»óµÇ°í ÀÖ½À´Ï´Ù.

KBV Cardinal matrix - ½ÉÀåÇÐ ºÐ¾ß ÀΰøÁö´É(AI) ½ÃÀå °æÀï ºÐ¼®

KBV Cardinal matrixÀÇ ºÐ¼®¿¡ µû¸£¸é, GE HealthCare Technologies, Inc.´Â ½ÉÀåÇÐ ºÐ¾ßÀÇ ÀΰøÁö´É(AI) ½ÃÀåÀ» ¼±µµÇϰí ÀÖ½À´Ï´Ù.2025³â 3¿ù, GE HealthCare Technologies, Inc. ¹«Á¦ÇÑ ¿øºñÆ® ½ÉÀå ¿µ»ó ÃÔ¿µ°ú ÷´Ü AI žÀç ¼Ö·ç¼ÇÀ» °®Ãá Revolution Vibe CT ½Ã½ºÅÛÀ» ¹ßÇ¥Çß½À´Ï´Ù. Áø´Ü Á¤È®µµ¿Í ¿öÅ©Ç÷οì È¿À²¼ºÀ» Çâ»ó½Ã۱â À§ÇØ ¼³°èµÈ ÀÌ ½Ã½ºÅÛÀº ¿øºñÆ®·Î °íÈ­Áú ¿µ»óÀ» Á¦°øÇÕ´Ï´Ù. Viz.ai, Tempus AI, Koninklijke Philips NV¿Í °°Àº ±â¾÷µéÀº ½ÉÀåÇÐ ºÐ¾ßÀÇ ÀΰøÁö´É(AI) ½ÃÀåÀÇ ÁÖ¿ä Çõ½Å°¡µéÀÔ´Ï´Ù.

Äڷγª19ÀÇ ¿µÇ⠺м®

Äڷγª19 ÆÒµ¥¹ÍÀº ½ÉÀåÇÐ ºÐ¾ßÀÇ ÀΰøÁö´É(AI) ½ÃÀå¿¡ º¯È­¸¦ °¡Á®¿ÔÀ¸¸ç, ´Ù¾çÇÑ ÇüÅ·Π¹ßÀü°ú µµÀÔÀ» ÃËÁøÇß½À´Ï´Ù. ´ÙÀ½Àº ½ÃÀå Á¶»ç µ¥ÀÌÅÍ¿¡ ÀÇÁ¸ÇÏÁö ¾Ê°í ÀϹÝÀûÀÎ µ¿Çâ°ú Æ®·»µå¿¡ ÃÊÁ¡À» ¸ÂÃá °ú°ÅÇüÀ¸·Î ±â¼úµÈ ÁÖ¿ä ¿µÇâÀÔ´Ï´Ù. ÆÒµ¥¹ÍÀº ¿ø°Ý ÀÇ·á ¼Ö·ç¼ÇÀÇ Çʿ伺À» °­Á¶ÇÏ°í ½ÉÀåÇÐ ºÐ¾ß¿¡¼­ AIÀÇ º¸±ÞÀ» ÃËÁøÇß½À´Ï´Ù. ÀÌó·³ Äڷγª19 ÆÒµ¥¹ÍÀº ½ÃÀå¿¡ ±àÁ¤ÀûÀÎ ¿µÇâÀ» ¹ÌÃÆ½À´Ï´Ù.

½ÃÀå ¼ºÀå ¿äÀÎ

½ÉÇ÷°ü ÁúȯÀº Àü ¼¼°èÀûÀ¸·Î ¿©ÀüÈ÷ ÀÌȯÀ²°ú »ç¸Á·üÀÇ ÁÖ¿ä ¿øÀÎÀÌ µÇ°í ÀÖ½À´Ï´Ù. °í·ÉÈ­, ¿îµ¿ ºÎÁ·, °Ç°­¿¡ ÇØ·Î¿î ½Ä½À°ü, Èí¿¬, ´ç´¢º´ ¹× °íÇ÷¾Ð Áõ°¡·Î ÀÎÇØ ½ÉÇ÷°ü Áúȯ(CVD)ÀÇ À¯º´·üÀÌ Å©°Ô Áõ°¡Çϰí ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ Áúº´ ºÎ´ã Áõ°¡´Â ÀÇ·á ½Ã½ºÅÛ¿¡ ÇÕº´Áõ°ú »ç¸Á·üÀ» ÁÙÀ̱â À§ÇØ ½Å¼ÓÇϰí Á¤È®ÇÑ Áø´Ü°ú È¿°úÀûÀÎ °ü¸®¸¦ Á¦°øÇØ¾ß ÇÑ´Ù´Â Å« ¾Ð¹ÚÀ» °¡Çϰí ÀÖ½À´Ï´Ù. ÀÌó·³ ½ÉÇ÷°ü ÁúȯÀÇ ¹ßº´·ü Áõ°¡¿Í Á¶±â ¹× Á¤È®ÇÑ Áø´ÜÀÇ Çʿ伺Àº ½ÉÀ庴Çп¡¼­ AIÀÇ ¹ßÀüÀ» À̲ô´Â ±Ùº»ÀûÀÎ ¿äÀÎÀ¸·Î ÀÛ¿ëÇϰí ÀÖÀ¸¸ç, ÀÌ·¯ÇÑ ±â¼úÀº Àü ¼¼°è ½ÉÀ庴ÀÇ °Ç°­ À§±â¿¡ ¸Â¼­ ½Î¿ì´Â µ¥ ÇʼöÀûÀÎ µµ±¸·Î ÀÚ¸®¸Å±èÇϰí ÀÖ½À´Ï´Ù.

¶ÇÇÑ, ÀÇ·á ¿µ»ó ±â¼ú°ú µ¥ÀÌÅÍ ºÐ¼® ´É·ÂÀÇ ±Þ¼ÓÇÑ ¹ßÀüÀº ½ÉÀ庴Çп¡ AI¸¦ ÅëÇÕÇÏ´Â Áß¿äÇÑ ¿øµ¿·ÂÀÌ µÇ°í ÀÖ½À´Ï´Ù. ½ÉÃÊÀ½ÆÄ, ½ÉÀå ÀÚ±â°ø¸í¿µ»ó(MRI), ÄÄÇ»ÅÍ ´ÜÃþÃÔ¿µ(CT), ÇÙÀÇÇÐ ¿µ»óÁø´Ü°ú °°Àº Çö´ëÀÇ ½ÉÇ÷°ü ¿µ»ó ±â¼úÀº ¸Å¿ì »ó¼¼ÇÏ°í ¹æ´ëÇÑ µ¥ÀÌÅÍ ¼¼Æ®¸¦ »ý¼ºÇÕ´Ï´Ù. ÀÌ·¯ÇÑ µ¥ÀÌÅ͸¦ Á¤È®ÇÏ°Ô ÇØ¼®Çϱâ À§Çؼ­´Â Àü¹® Áö½Ä°ú ¸¹Àº ½Ã°£ ÅõÀÚ°¡ ÇÊ¿äÇÕ´Ï´Ù. µû¶ó¼­ ÀÇ·á ¿µ»ó ¹× µ¥ÀÌÅÍ ºÐ¼® ±â¼úÀÇ ¹ßÀüÀº ½ÉÀåÇÐ ºÐ¾ß¿¡¼­ AI ¼Ö·ç¼ÇÀÇ µµÀÔ°ú È¿°ú¸¦ °¡¼ÓÈ­ÇÏ´Â °­·ÂÇÑ Ã˸ÅÁ¦°¡ µÉ °ÍÀ̸ç, ±Ã±ØÀûÀ¸·Î ½ÉÀå Ä¡·á Á¦°ø¿¡ º¯È­¸¦ °¡Á®¿Ã °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù.

½ÃÀå ¼ºÀå ¾ïÁ¦¿äÀÎ

½ÉÀåÇÐ ºÐ¾ß¿¡¼­ ÀΰøÁö´É(AI)ÀÇ ±¤¹üÀ§ÇÑ µµÀÔÀ» °¡·Î¸·´Â °¡Àå ½É°¢ÇÑ Á¦¾à Áß Çϳª´Â µ¥ÀÌÅÍ ÇÁ¶óÀ̹ö½Ã ¹× º¸¾È¿¡ ´ëÇÑ ¿ì·Á Áõ°¡ÀÔ´Ï´Ù. ½ÉÇ÷°ü AI ¿ëµµ´Â °³ÀÎ ½Äº° Á¤º¸, º´·Â, À̹ÌÁö ½ºÄµ, ½Ç½Ã°£ ¸ð´ÏÅ͸µ µ¥ÀÌÅÍ µî ¹æ´ëÇÑ ¾çÀÇ ¹Î°¨ÇÑ È¯ÀÚ °Ç°­ µ¥ÀÌÅÍÀÇ ¼öÁý, ÀúÀå ¹× ºÐ¼®¿¡ Å©°Ô ÀÇÁ¸Çϰí ÀÖ½À´Ï´Ù. º´¿ø, ¿þ¾î·¯ºí ±â±â, ¸ð¹ÙÀÏ ¾ÖÇø®ÄÉÀÌ¼Ç µî ¿©·¯ ¼Ò½º·ÎºÎÅÍ ¼öÁýµÇ´Â ÀÌ ¹æ´ëÇÑ µ¥ÀÌÅÍ´Â »çÀ̹ö ¹üÁËÀڵ鿡°Ô ÁÁÀº Ç¥ÀûÀÌ µÉ ¼ö ÀÖ½À´Ï´Ù. µû¶ó¼­ µ¥ÀÌÅÍ ÇÁ¶óÀ̹ö½Ã ¹× º¸¾È¿¡ ´ëÇÑ ¿ì·Á´Â ½ÃÀå¿¡¼­ ½É°¢ÇÑ Á¦¾àÀÌ µÇ°í ÀÖÀ¸¸ç, ȯÀÚÀÇ ½Å·Ú¿Í ¾ÈÀüÇÑ AI µµÀÔÀ» ÃËÁøÇϱâ À§ÇØ ¾ö°ÝÇÑ ¾ÈÀü Á¶Ä¡¿Í À±¸® ±âÁØÀÌ ¿ä±¸µÇ°í ÀÖ½À´Ï´Ù.

°¡Ä¡»ç½½ ºÐ¼®

½ÉÀåÇÐ ºÐ¾ßÀÇ ÀΰøÁö´É(AI) ½ÃÀå °¡Ä¡»ç½½ ºÐ¼®Àº ¿¬±¸°³¹ß¿¡¼­ ÃÖÁ¾ »ç¿ëÀÚ¿¡ ´ëÇÑ µµÀÔ±îÁö Á¾ÇÕÀûÀÎ È帧À» º¸¿©ÁÝ´Ï´Ù. ±âº» R&D Ȱµ¿¿¡¼­ ½ÃÀÛÇÏ¿© AI ¸ðµ¨ ÇнÀ¿¡ ÇʼöÀûÀÎ µ¥ÀÌÅÍ ¼öÁý ¹× °ü¸®·Î À̾îÁý´Ï´Ù. ÀÌ ÇÁ·Î¼¼½º´Â ¸ðµ¨ °³¹ß ¹× ÈÆ·Ã, ±ÔÁ¦ ´ç±¹ÀÇ ½ÂÀÎ ¹× ÀÎÁõÀ¸·Î À̾îÁý´Ï´Ù. ½ÂÀÎ ÈÄ¿¡´Â ÇコÄÉ¾î ½Ã½ºÅÛ ³»¿¡¼­ Á¦Ç° ÅëÇÕ ¹× ¹èÆ÷°¡ ÀÌ·ç¾îÁý´Ï´Ù. ¸¶ÄÉÆÃ ¹× ÆÇ¸Å´Â Ÿ°ÙÆÃµÈ ÇÁ·Î¸ð¼ÇÀ» ÅëÇØ µµÀÔÀ» ÃËÁøÇÕ´Ï´Ù. ¾ÖÇÁÅÍ ¼¼ÀÏÁî Áö¿ø ¹× Çǵå¹é ·çÇÁ¿¡¼­´Â Áö¼ÓÀûÀÎ Çǵå¹éÀ» ÅëÇØ ¼Ö·ç¼ÇÀ» °­È­ÇÕ´Ï´Ù.

½ÃÀå Á¡À¯À² ºÐ¼®

ÄÄÆ÷³ÍÆ® Àü¸Á

½ÃÀåÀº ±¸¼º ¿ä¼Ò, Çϵå¿þ¾î, ¼ÒÇÁÆ®¿þ¾î, ¼­ºñ½º¸¦ ±âÁØÀ¸·Î ºÐ·ùµË´Ï´Ù. ¼ÒÇÁÆ®¿þ¾î ºÎ¹®Àº 2024³â ½ÃÀå¿¡¼­ 34%ÀÇ ¸ÅÃâ Á¡À¯À²À» Â÷ÁöÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù. ÀÌ ºÎ¹®¿¡´Â ½ÉÀå Àü¹®ÀÇÀÇ ÀÓ»ó ÀÇ»ç °áÁ¤, ¿¹Ãø ºÐ¼®, ¿µ»ó ºÐ¼®, ȯÀÚ À§Çè Æò°¡¸¦ Áö¿øÇϱâ À§ÇØ ¼³°èµÈ ´Ù¾çÇÑ AI Áö¿ø ¼ÒÇÁÆ®¿þ¾î Ç÷§ÆûÀÌ Æ÷ÇԵ˴ϴÙ. ½ÉÀåÇÐ ºÐ¾ßÀÇ AI ¼ÒÇÁÆ®¿þ¾î´Â ½ÉÃÊÀ½ÆÄ, CT ½ºÄµ, ½ÉÀüµµ µ¥ÀÌÅÍ, ÀüÀÚ °Ç°­ ±â·ÏÀ» ºÐ¼®Çϱâ À§ÇØ ¸Ó½Å·¯´× ¾Ë°í¸®Áò, µö·¯´× ÇÁ·¹ÀÓ¿öÅ©, ÀÚ¿¬¾î ó¸® µµ±¸¸¦ ÅëÇÕÇÏ´Â °æ¿ì°¡ ¸¹½À´Ï´Ù.

¿ëµµ Àü¸Á

¿ëµµº°·Î ½ÃÀåÀº Áø´Ü, ¿¹Ãø, ½Å¾à°³¹ß, ±âŸ·Î ºÐ·ùµË´Ï´Ù. ¿¹Ãø ºÎ¹®Àº 2024³â Àüü ½ÃÀå ¸ÅÃâÀÇ 29%¸¦ Â÷ÁöÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù. ÀÌ ºÎ¹®¿¡´Â °ú°Å µ¥ÀÌÅÍ, À¯Àü Á¤º¸, »ýȰ½À°ü ¿äÀÎ, Áö¼ÓÀûÀÎ ¸ð´ÏÅ͸µ µ¥ÀÌÅ͸¦ ±â¹ÝÀ¸·Î ÀáÀçÀûÀÎ ½ÉÀ帶ºñ ¹× ȯÀÚ °á°ú¸¦ ¿¹ÃøÇÏ´Â AI µµ±¸°¡ Æ÷ÇԵ˴ϴÙ. ¸Ó½Å·¯´× ¸ðµ¨À» Ȱ¿ëÇÑ ¿¹Ãø ºÐ¼®Àº ÀÇ·áÁøÀÌ ½ÉÀ帶ºñ, ³úÁ¹Áß, ½ÉºÎÀü µîÀÇ Áúº´ À§ÇèÀ» Æò°¡ÇÏ°í ¿¹¹æÀû °³ÀÔ ¹× °³ÀÎÈ­µÈ Ä¡·á Àü·«À» ¼ö¸³ÇÏ´Â µ¥ µµ¿òÀ» ÁÝ´Ï´Ù.

º´»ó Àü¸Á

Áúȯº°·Î´Â ÇãÇ÷¼º ½ÉÀåÁúȯ(CAD), ºÎÁ¤¸Æ, ½ÉºÎÀü, ±âŸ·Î ºÐ·ùµË´Ï´Ù. ºÎÁ¤¸Æ ºÎ¹®Àº 2024³â 20% ½ÃÀå Á¡À¯À²À» Â÷ÁöÇÒ °ÍÀ¸·Î ¿¹»óµÇ¸ç, AI µµ±¸´Â ½É¹æ¼¼µ¿°ú °°Àº ºÎÁ¤¸ÆÀ» °¨ÁöÇÏ°í ¸ð´ÏÅ͸µÇÏ´Â µ¥ ³Î¸® Ȱ¿ëµÇ°í ÀÖ½À´Ï´Ù. AI ¾Ë°í¸®ÁòÀº ½ÉÀüµµ µ¥ÀÌÅÍ¿Í ¿þ¾î·¯ºí ±â±âÀÇ Ãâ·ÂÀ» ºÐ¼®ÇÏ¿© ºñÁ¤»óÀûÀÎ ÆÐÅÏÀ» ½Äº°Çϰí ÀÇ·áÁø¿¡°Ô ½Ç½Ã°£À¸·Î ¾Ë·ÁÁÖ´Â AI ¾Ë°í¸®ÁòÀ» ÅëÇØ ÀÌ·¯ÇÑ ºÎÁ¤¸ÆÀ» Á¶±â¿¡ ¹ß°ßÇÒ ¼ö ÀÖ½À´Ï´Ù.

Áö¿ª Àü¸Á

Áö¿ªº°·Î´Â ºÏ¹Ì, À¯·´, ¾Æ½Ã¾ÆÅÂÆò¾ç, ¶óƾ¾Æ¸Þ¸®Ä«, Áßµ¿ ¹× ¾ÆÇÁ¸®Ä«·Î ½ÃÀåÀ» ºÐ¼®Çß½À´Ï´Ù. ºÏ¹Ì ºÎ¹®Àº 2024³â ½ÃÀå ¸ÅÃâ Á¡À¯À²ÀÇ 43%¸¦ Â÷ÁöÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù. ÀÌ·¯ÇÑ ¼ºÀåÀº ÁַΠ÷´Ü ÀÇ·á ÀÎÇÁ¶óÀÇ Á¸Àç, AI ¹× ÀÇ·á ±â¼ú ±â¾÷ÀÇ ÁýÁß, ±×¸®°í µðÁöÅÐ °Ç°­¿¡ ´ëÇÑ Àû±ØÀûÀÎ ÅõÀÚ¿¡ ±âÀÎÇÕ´Ï´Ù. ƯÈ÷ ¹Ì±¹Àº ½ÉÀ庴ÇÐ ºÐ¾ß¿¡¼­ AI ÅëÇÕÀÇ ÃÖÀü¼±¿¡ ¼­¼­ ¸Ó½Å·¯´×, µö·¯´×, ¿¹Ãø ºÐ¼® µîÀÇ ±â¼úÀ» Ȱ¿ëÇÏ¿© ½ÉÇ÷°ü Áø´Ü, Ä¡·á °èȹ, ȯÀÚ ¸ð´ÏÅ͸µÀ» °³¼±Çϰí ÀÖ½À´Ï´Ù.

½ÃÀå °æÀï°ú Ư¼º

½ÉÀåÇÐ ºÐ¾ßÀÇ ÀΰøÁö´É(AI) ½ÃÀåÀº °æÀïÀÌ Ä¡¿­ÇÕ´Ï´Ù. ¸¹Àº ½ºÅ¸Æ®¾÷°ú ¿¬±¸ ±â¹Ý ½ºÅ¸Æ®¾÷µéÀÌ ½ÉÀüµµ ºÐ¼®, ½ÉÀå ¿µ»ó Áø´Ü, ¿¹Ãø ºÐ¼® µîÀÇ ºÐ¾ß¿¡¼­ Àû±ØÀûÀ¸·Î Çõ½ÅÀ» ÀÏÀ¸Å°°í ÀÖ½À´Ï´Ù. Á¤¹Ð ½ÉÀåÇп¡ ´ëÇÑ ¼ö¿ä°¡ Áõ°¡ÇÔ¿¡ µû¶ó, ÀÌµé ±â¾÷Àº ÀÓ»ó °ËÁõ, AI Çõ½Å, Àü·«Àû ÆÄÆ®³Ê½Ê, ±ÔÁ¦ ´ç±¹ÀÇ ½ÂÀΠȹµæÀ» À§ÇØ Ä¡¿­ÇÑ °æÀïÀ» ¹úÀ̸ç È®°íÇÑ ½ÃÀå ±â¹ÝÀ» ±¸ÃàÇϱâ À§ÇØ ³ë·ÂÇϰí ÀÖ½À´Ï´Ù.

¸ñÂ÷

Á¦1Àå ½ÃÀå ¹üÀ§¿Í Á¶»ç ¹æ¹ý

Á¦2Àå ½ÃÀå °³°ü

Á¦3Àå ½ÃÀå °³¿ä

Á¦4Àå °æÀï ºÐ¼® - ¼¼°è

Á¦5Àå ½ÉÀåÇÐ ºÐ¾ß ÀΰøÁö´É(AI) ½ÃÀå ¹ë·ùüÀÎ ºÐ¼®

Á¦6Àå ÁÖ¿ä °í°´ ±âÁØ - ½ÉÀåÇÐ ºÐ¾ß ÀΰøÁö´É(AI) ½ÃÀå

Á¦7Àå ¼¼°èÀÇ ½ÉÀåÇÐ ºÐ¾ß ÀΰøÁö´É(AI) ½ÃÀå : ÄÄÆ÷³ÍÆ®º°

Á¦8Àå ¼¼°èÀÇ ½ÉÀåÇÐ ºÐ¾ß ÀΰøÁö´É(AI) ½ÃÀå : ¿ëµµº°

Á¦9Àå ¼¼°èÀÇ ½ÉÀåÇÐ ºÐ¾ß ÀΰøÁö´É(AI) ½ÃÀå : º´»óº°

Á¦10Àå ¼¼°èÀÇ ½ÉÀåÇÐ ºÐ¾ß ÀΰøÁö´É(AI) ½ÃÀå : Áö¿ªº°

Á¦11Àå ±â¾÷ °³¿ä

Á¦12Àå ½ÉÀåÇÐ ºÐ¾ß ÀΰøÁö´É(AI) ½ÃÀåÀ» À§ÇÑ ¼º°ø Çʼö Á¶°Ç

LSH
¿µ¹® ¸ñÂ÷

¿µ¹®¸ñÂ÷

The Global Artificial Intelligence In Cardiology Market size is expected to reach $18.21 billion by 2032, rising at a market growth of 32.3% CAGR during the forecast period.

One of the key trends in hardware for AI in cardiology is the growing adoption of edge computing devices that can process data locally within hospital or clinical environments. This reduces latency and enhances data privacy-a critical factor in healthcare. Furthermore, specialized AI chips, such as neural processing units (NPUs), are being incorporated into medical imaging systems and diagnostic devices to support real-time cardiac assessments.

The major strategies followed by the market participants are Product Launches as the key developmental strategy to keep pace with the changing demands of end users. For instance, In April, 2025, Tempus AI, Inc. unveiled a multi-center study titled "Electrocardiogram-based Artificial Intelligence-Assisted Detection of Heart Disease" (ECG-AID), focusing on evaluating the impact of AI-enabled predictive tests in cardiology . These efforts demonstrate Tempus' commitment to leveraging AI in the cardiology sector. Additionally, In April, 2025, Viz.ai, Inc. unveiled Viz 3D CTA, an AI-powered imaging solution designed to enhance 3D visualization of CT angiography. The technology improves diagnostic accuracy and speeds up clinical decision-making, especially in cardiology and stroke care, supporting faster interventions and improved patient outcomes through advanced artificial intelligence and automated workflows.

KBV Cardinal Matrix - Artificial Intelligence In Cardiology Market Competition Analysis

Based on the Analysis presented in the KBV Cardinal matrix; GE HealthCare Technologies, Inc. is the forerunner in the Artificial Intelligence In Cardiology Market. In March, 2025, GE HealthCare Technologies, Inc. unveiled the Revolution Vibe CT system, featuring Unlimited One-Beat cardiac imaging and advanced AI-powered solutions. Designed to enhance diagnostic accuracy and workflow efficiency, the system delivers high-quality images in a single heartbeat. It aims to improve patient outcomes and streamline operations in clinical environments. Companies such as Viz.ai, Inc., Tempus AI, Inc., and Koninklijke Philips N.V., and are some of the key innovators in Artificial Intelligence In Cardiology Market.

COVID 19 Impact Analysis

The COVID-19 pandemic had a transformative impact on the Artificial Intelligence (AI) in cardiology market, driving advancements and adoption in several positive ways. Below are key impacts described in past tense, focusing on general trends and developments without relying on market research data: The pandemic spurred widespread use of AI in cardiology by emphasizing the need for remote healthcare solutions. Thus, the COVID-19 pandemic had a positive impact on the market.

Market Growth Factors

Cardiovascular diseases remain the leading cause of morbidity and mortality worldwide. Factors such as aging populations, sedentary lifestyles, poor diets, smoking, and rising incidences of diabetes and hypertension have significantly escalated the prevalence of CVDs. This growing disease burden places immense pressure on healthcare systems to provide timely and accurate diagnoses and effective management to reduce complications and mortality. Thus, the rising incidence of cardiovascular diseases coupled with the critical need for early and accurate diagnosis represents a fundamental driver for the growth of AI in cardiology, positioning these technologies as essential tools in combating the global cardiac health crisis.

Additionally, the rapid evolution of medical imaging technologies and data analytics capabilities has been a key driver propelling AI integration into cardiology. Modern cardiovascular imaging techniques-such as echocardiography, cardiac magnetic resonance imaging (MRI), computed tomography (CT), and nuclear imaging-generate highly detailed and voluminous datasets. Interpreting this data accurately requires specialized expertise and significant time investment. Therefore, advancements in medical imaging and data analytics technologies serve as a powerful catalyst accelerating the adoption and effectiveness of AI solutions within cardiology, ultimately transforming cardiac care delivery.

Market Restraining Factors

One of the most significant restraints impeding the widespread adoption of artificial intelligence in cardiology is the growing concern over data privacy and security. Cardiovascular AI applications depend heavily on collecting, storing, and analyzing vast amounts of sensitive patient health data, including personal identifiers, medical histories, imaging scans, and real-time monitoring data. This enormous volume of data, often aggregated from multiple sources such as hospitals, wearable devices, and mobile applications, presents a lucrative target for cybercriminals. Thus, data privacy and security concerns act as a critical restraint on the market, necessitating stringent safeguards and ethical standards to foster patient trust and safe AI deployment.

Value Chain Analysis

The value chain analysis of the Artificial Intelligence in Cardiology Market highlights a comprehensive flow from Research and Development to End-User Adoption. It begins with foundational R&D Activities, followed by Data Acquisition & Management, essential for training AI models. The process moves into Model Development & Training, leading to Regulatory Approvals and Certifications. Once approved, Product Integration & Deployment take place within healthcare systems. Marketing and Sales Driving adoption through targeted promotion. After-Sales Support & Feedback Loop Enhancing solutions via continuous feedback.

Market Share Analysis

Component Outlook

Based on component, the market is characterized into hardware, software, and services. The software segment garnered 34% revenue share in the market in 2024. This segment includes a wide range of AI-enabled software platforms designed to assist cardiologists in clinical decision-making, predictive analysis, image interpretation, and patient risk assessment. AI software in cardiology often incorporates machine learning algorithms, deep learning frameworks, and natural language processing tools to analyze echocardiograms, CT scans, ECG data, and electronic health records.

Application Outlook

On the basis of application, the market is classified into diagnosis, prediction, drug discovery, and others. The prediction segment recorded 29% revenue share in the market in 2024. This segment encompasses AI tools used to forecast potential cardiac events and patient outcomes based on historical data, genetic information, lifestyle factors, and continuous monitoring inputs. Predictive analytics powered by machine learning models help healthcare professionals assess the risk of conditions such as heart attacks, strokes, and heart failure, allowing for preemptive interventions and personalized care strategies.

Medical Condition Outlook

By medical condition, the market is divided into ischemic heart disease /CAD, cardiac arrhythmias, heart failure, and others. The cardiac arrhythmias segment garnered 20% revenue share in the market in 2024. AI tools are being used extensively to detect and monitor irregular heart rhythms, such as atrial fibrillation, which often go unnoticed in their early stages. By analyzing ECG data and wearable device outputs, AI algorithms can identify abnormal patterns and notify healthcare providers in real time.

Regional Outlook

Region-wise, the market is analyzed across North America, Europe, Asia Pacific, and LAMEA. The North America segment recorded 43% revenue share in the market in 2024. This growth is primarily attributed to the presence of advanced healthcare infrastructure, a high concentration of AI and healthcare technology companies, and strong investments in digital health initiatives. The United States, in particular, has been at the forefront of AI integration in cardiology, leveraging technologies such as machine learning, deep learning, and predictive analytics to improve cardiovascular diagnostics, treatment planning, and patient monitoring.

Market Competition and Attributes

The competition in the Artificial Intelligence in Cardiology market is high. Numerous emerging companies and research-based startups are aggressively innovating in areas like ECG analysis, cardiac imaging, and predictive analytics. With increasing demand for precision cardiology, these players compete fiercely for clinical validation, AI breakthroughs, strategic partnerships, and regulatory clearances to establish a strong market foothold.

Recent Strategies Deployed in the Market

List of Key Companies Profiled

Global Artificial Intelligence In Cardiology Market Report Segmentation

By Component

By Application

By Medical Condition

By Geography

Table of Contents

Chapter 1. Market Scope & Methodology

Chapter 2. Market at a Glance

Chapter 3. Market Overview

Chapter 4. Competition Analysis - Global

Chapter 5. Value Chain Analysis of Artificial Intelligence In Cardiology Market

Chapter 6. Key Customer Criteria - Artificial Intelligence In Cardiology Market

Chapter 7. Global Artificial Intelligence In Cardiology Market by Component

Chapter 8. Global Artificial Intelligence In Cardiology Market by Application

Chapter 9. Global Artificial Intelligence In Cardiology Market by Medical Condition

Chapter 10. Global Artificial Intelligence In Cardiology Market by Region

Chapter 11. Company Profiles

Chapter 12. Winning Imperatives of Artificial Intelligence In Cardiology Market

(ÁÖ)±Û·Î¹úÀÎÆ÷¸ÞÀÌ¼Ç 02-2025-2992 kr-info@giikorea.co.kr
¨Ï Copyright Global Information, Inc. All rights reserved.
PC¹öÀü º¸±â